Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma through Induction of FLIP.

Lia Perez, MD, Nancy Parquet, BS, Ken Shain, Ph.D. M.D., Ramadevi Nimmanapalli, D.V.M. Ph.D, Melissa Alsina, M.D., Claudio Anasetti, M.D., William S. Dalton, Ph.D. M.D.

Blood (2006) 108 (11): 3424.

https://doi.org/10.1182/blood.V108.11.3424.3424

Published: 2006

Journal Articles

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Ramadevi Nimmanapalli, DVM, PhD, Melissa Alsina, M.D, Claudio Anasetti, MD, William Dalton, PhD MD

Blood (2005) 106 (11): 2489.

https://doi.org/10.1182/blood.V106.11.2489.2489

Published: 2005

Journal Articles

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Nancy Parquet, B.S., Ramadevi Nimmanapalli, D.V.M. Ph.D., Claudio Anasetti, M.D., Melissa Alsina, M.D., William Dalton, Ph.D. M.D., Lia E. Perez, M.D.

Blood (2004) 104 (11): 2459.

https://doi.org/10.1182/blood.V104.11.2459.2459

Published: 2004

Journal Articles

Adhesion of 8226 Myeloma Cell Lines Induces over Expression of HSP70 and its Inhibition Reverses CAM-DR and Acquired Drug Resistance in Multiple Myeloma.

Ramadevi Nimmanapalli, P.hD, Elvira Gerbino, MSc, William S. Dalton, M.D.,P.hD, Melissa Alsina, M.D

Blood (2004) 104 (11): 636.

https://doi.org/10.1182/blood.V104.11.636.636

Published: 2004

Journal Articles

HSP70 Induces IL-6 in Stromal Cells and Stat-3 Activation in Myeloma Cells.

Ramadevi Nimmanapalli, PhD, Elvira Gerbino, MSc, William S. Dalton, M.D.P.hD, Melissa Alsina, M.D

Blood (2004) 104 (11): 3353.

https://doi.org/10.1182/blood.V104.11.3353.3353

Published: 2004

Journal Articles

Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling.

Ramadevi Nimmanapalli, Ph.D, Lori Hazlehurst, Ph.D, Steven Enkemann, Ph.D, Melissa Alsina, M.D., William S. Dalton, M.D., Ph.D

Blood (2004) 104 (11): 3357.

https://doi.org/10.1182/blood.V104.11.3357.3357

Published: 2004

NARROW

Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma through Induction of FLIP.

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Adhesion of 8226 Myeloma Cell Lines Induces over Expression of HSP70 and its Inhibition Reverses CAM-DR and Acquired Drug Resistance in Multiple Myeloma.

HSP70 Induces IL-6 in Stromal Cells and Stat-3 Activation in Myeloma Cells.

Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling.

Email alerts

ASH Publications

American Society of Hematology

Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma through Induction of FLIP.

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Adhesion of 8226 Myeloma Cell Lines Induces over Expression of HSP70 and its Inhibition Reverses CAM-DR and Acquired Drug Resistance in Multiple Myeloma.

HSP70 Induces IL-6 in Stromal Cells and Stat-3 Activation in Myeloma Cells.

Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only